Fluoroquinolones efficacy in acute sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections | CMAC

Fluoroquinolones efficacy in acute sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):25-30

​ Ushkalova E.A., Zyryanov S.K.
fluoroquinolones acute sinusitis acute exacerbation of chronic bronchitis uncomplicated urinary tract infections
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):25-30

Abstract

In May 2016 the U.S. Food and Drug Administration (FDA) approved changes to the labels of fluoroquinolone drugs for systemic use and advised to restrict their prescribing for the treatment of acute sinusitis, uncomplicated urinary tract infections and acute exacerbation of chronic bronchitis. This decision followed the recommendation of FDA Advisory Committees which concluded that the risk of rare serious and potentially permanent side effects of musculoskeletal, central and peripheral nervous system that can occur together in the same patient outweighed fluoroquinolones benefits in these infections. The article reviews data about fluoroquinolones and other antibiotics efficacy in acute sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections presented at FDA Advisory Committee meeting and published in available scientific literature.

Elena A. Ushkalova

RUDN University, Moscow, Russia

Sergey K. Zyryanov

RUDN University, Moscow, Russia

  • 1. Douros A, Grabowski K, Stahlmann R. Safety issues and drug-drug interactions with commonly used quinolones. USExpert Opin Drug Metab Toxicol 2015;11(1):25-39.
  • 2. Kubanov A, Vorobyev D, Chestkov A, Leinsoo A, Shaskolskiy B, Dementieva E, et al. Molecular epidemiology of drug-resistant Neisseria gonorrhoeae in Russia (Current Status, 2015). BMC Infect Dis 2016;16:389.
  • 3. National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 200
  • 4. Am J Infect Control 2004;32(8):470-84.
  • 5. Kim M, Lloyd A, Condren M, Miller MJ. Beyond antibiotic selection: concordance with the IDSA guidelines for uncomplicated urinary tract infections. Infection 2015;43:89-94. 5. Ho PL, Que TL, Chiu SS, Yung RW, Ng TK, Tsang DN, et al. Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995-2001. Emerg Infect Dis 2004;10(7):1250-7.
  • 6. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf. 2013;12(4):497-505.
  • 7. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together [05-12-2016].
  • 8. Tillotson GS. FDA and the safe and appropriate antibiotic use of fluoroquinolones. Lancet Infect Dis 2016;16(3):e11-2.
  • 9. Vance M. New FDA restrictions for fluoroquinolones. Cleveland Clinic Clinical R Forum 2016;4(4):1-2.
  • 10. FDA Briefing Document. Joint meeting of the Antimicrobial drugs advisory committee and the Drug safety and risk management advisory committee November 5, 2015 г. The Benefits and Risks of Systemic Fluoroquinolone Antibacterial Drugs for the Treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation of Chronic Bronchitis in Patients Who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD),and Uncomplicated Urinary Tract Infections (uUTI). Available at URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM467383.pdf.
  • 11. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015;152 (Suppl 2):S1-S39.
  • 12. Young J, A De Sutter, D Merenstein, et al. Antibiotics for Adults With Clinically Diagnosed Acute Rhinosinusitis: a Meta-analysis of Individual Patient Data. Lancet 2008;371:908-13.
  • 13. Falagas ME, Giannopoulou KP, Vardakas KZ, et al. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:543.
  • 14. Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, et al. Antibiotics for acute maxillary sinusitis in adults. Cochrane Database Syst Rev 2014;CD000243.
  • 15. Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. Cochrane Database Syst Rev 2012;10:CD006089.
  • 16. Karageorgopoulos DE, Giannopoulou KP, Grammatikos AP, Dimopoulos G, Falagas ME. Fluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. CMAJ 2008;178(7):845-54.
  • 17. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Advice for High-Value Care From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2016;164(6):425-34.
  • 18. Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment (last updated: Sep 13, 2016). Available at URL: http://www.uptodate.com/contents/uncomplicated-acute-sinusitis-andrhinosinusitis-in-adults-treatment
  • 19. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, Pankey GA, Seleznick M, Volturo G, Wald ER, File TM Jr; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis 2012;54(8):e72-e112.
  • 20. Mehrotra A, Linder JA. Tipping the balance toward fewer antibiotics. JAMA Intern Med. 2016;176(11):1649-50.
  • 21. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016;315 (17):1864-73.
  • 22. Nouria S, Marghi S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001;358(9298):2020-5.
  • 23. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(2):CD004403.
  • 24. Sethi S, Murphy TF. Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease, New Engl J Med 2008;359:2355-65.
  • 25. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, Yang IA. Acute exacerbation of COPD. Respirology 2016;21(7):1152-65.
  • 26. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;12:CD010257.
  • 27. Echols RM, Tosiello R, Garfield M, et al. Superiority of an antibiotic (feropenem medoxomil) versus placebo in the treatment of AECB. The 48th Annual ICAAC – IDSA 46th Annual Meeting 2008.
  • 28. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(2):CD004403.
  • 29. Laue J, Reierth E, Melbye H.When should acute exacerbations of COPD be treated with systemic corticosteroids and antibiotics in primary care: a systematic review of current COPD guidelines. NPJ Prim Care Respir Med 2015;25:15002.
  • 30. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2015. Available at URL: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf.
  • 31. Liu KX, Xu B, Wang J, Zhang J, Ding HB, Ariani F, et al. Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis. J Thorac Dis 2014;6(3):221-9.
  • 32. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5):e103-20.
  • 33. Перепанова ТС. Федеральные клинические рекомендации «Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов – 2015 г.» Терапевтический архив 2016;88(4):100-4.
  • 34. Gratacós E, Torres P, Vila J, Alonso PL, Cararach V. Screening and treatment of asymptomatic bacteriuria in pregnancy prevent pyelonephritis. J Infect Dis 1994;169:1390-2.
  • 35. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a metaanalysis of randomized controlled trials. J Infect 2009;58(2):91-102.
  • 36. Christiaens TC, De Meyere M, Verschraegen G, Peersman W, Heytens S, De Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002;52(482):729-34.
  • 37. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand J Infect Dis 2004;36(4):296- 301.
  • 38. Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 2010;340:199.
  • 39. Bleidorn J, Gágyor I, Kochen MM, Wegscheider K, Hummers-Pradier E. Symptomatic Treatment (ibuprofen) or Antibiotics (ciprofloxacin) for Uncomplicated Urinary Tract Infection?--Results of a Randomized Controlled Pilot Trial. BMC Med 2010;8:30.
  • 40. Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015;351:h6544.
  • 41. Zalmanovici TA, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010;(10):CD007182.
  • 42. Knottnerus BJ, Grigoryan L, Geerlings SE, Moll van Charante EP, Verheij TJ, Kessels AG, ter Riet G. Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials. Fam Pract 2012;29(6):659-70.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared